These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala. Flood JF; Garland JS; Morley JE Brain Res; 1992 Jul; 585(1-2):94-104. PubMed ID: 1511338 [TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide (VIP) causes memory impairment in passive avoidance responding of the rat. Takashima A; Maeda Y; Itoh S Peptides; 1993; 14(5):1067-71. PubMed ID: 8284258 [TBL] [Abstract][Full Text] [Related]
4. Modulation of memory processing by neuropeptide Y. Flood JF; Hernandez EN; Morley JE Brain Res; 1987 Sep; 421(1-2):280-90. PubMed ID: 3690274 [TBL] [Abstract][Full Text] [Related]
5. Dissociation of the effects of neuropeptide Y on feeding and memory: evidence for pre- and postsynaptic mediation. Flood JF; Morley JE Peptides; 1989; 10(5):963-6. PubMed ID: 2558366 [TBL] [Abstract][Full Text] [Related]
6. Effects of vasoactive intestinal peptide (VIP) on scopolamine-induced amnesia in the rat. Yamaguchi Y; Kobayashi H Neuropeptides; 1994 Mar; 26(3):153-8. PubMed ID: 8208360 [TBL] [Abstract][Full Text] [Related]
7. Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression. Ivanova M; Belcheva S; Belcheva I; Negrev N; Tashev R Psychopharmacology (Berl); 2012 Jun; 221(4):561-74. PubMed ID: 22160165 [TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin receptors mediate enhanced memory retention produced by feeding and gastrointestinal peptides. Flood JF; Morley JE Peptides; 1989; 10(4):809-13. PubMed ID: 2587422 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration. Cui X; Cao DY; Wang ZM; Zheng AP Pharmazie; 2013 Jan; 68(1):69-74. PubMed ID: 23444784 [TBL] [Abstract][Full Text] [Related]
15. Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Mazzola C; Micale V; Drago F Eur J Pharmacol; 2003 Sep; 477(3):219-25. PubMed ID: 14522360 [TBL] [Abstract][Full Text] [Related]
16. Novel peptide VIP-TAT with higher affinity for PAC1 inhibited scopolamine induced amnesia. Yu R; Yang Y; Cui Z; Zheng L; Zeng Z; Zhang H Peptides; 2014 Oct; 60():41-50. PubMed ID: 25086267 [TBL] [Abstract][Full Text] [Related]
17. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. Gozes I; McCune SK; Jacobson L; Warren D; Moody TW; Fridkin M; Brenneman DE J Pharmacol Exp Ther; 1991 Jun; 257(3):959-66. PubMed ID: 1646331 [TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide is a hypothalamic prolactin-releasing neuropeptide in the turkey (Meleagris gallopavo). el Halawani ME; Silsby JL; Mauro LJ Gen Comp Endocrinol; 1990 Apr; 78(1):66-73. PubMed ID: 2158920 [TBL] [Abstract][Full Text] [Related]
19. Alleviation of scopolamine amnesia by different retrieval enhancing treatments. Quartermain D; Leo P Pharmacol Biochem Behav; 1988 Aug; 30(4):1093-6. PubMed ID: 3227033 [TBL] [Abstract][Full Text] [Related]
20. Effect of acute arecoline, tacrine and arecoline + tacrine post-training administration on retention in old mice. Flood JF; Cherkin A Neurobiol Aging; 1988; 9(1):5-8. PubMed ID: 3380255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]